Successful ovulation induction by sandostatin-therapy of polycystic ovarian disease

Acta Obstetricia et Gynecologica Scandinavica

Volumn 75, Issue 3, 1996, Pages 298-299

  Wenzl, René ^a   Lehner, Rainer ^a   Schurz, Brigitte ^a   Karas, Hermann ^a   Huber, Johannes C ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Polycystic ovarian disease; Pregnancy; Sandostatin

Indexed keywords

HYPOTHALAMUS HORMONE; OCTREOTIDE;

ANOVULATION; ARTICLE; CASE REPORT; FEMALE; HUMAN; OVARY POLYCYSTIC DISEASE; OVULATION INDUCTION; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION;

ADULT; FEMALE; HUMANS; OCTREOTIDE; OVULATION INDUCTION; POLYCYSTIC OVARY SYNDROME; PREGNANCY; PREGNANCY COMPLICATIONS; PREGNANCY OUTCOME;

EID: 0029918662     PISSN: 00016349     EISSN: None     Source Type: Journal    
DOI: 10.3109/00016349609047106     Document Type: Article

References (3)

1. Vance ML, Harris AG. Long term treatment of 189 acromegalic patients with the somatostain analog octreotide: results of the International Multicenter Acromegaly Study Group. Arch Intern Med 1991; 151; 1573-8.
2. Editorial: Octreotide steaming ahead. Lancet 1992; 339; 837-9.
3. Prelevic GM et al. Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet 1990; 336; 900-3.